City

Columbus (1)

San Francisco (1)

Overall Status

Terminated (1)

Withdrawn (1)

Sign in for free

Phase

phase 2 (2)

Sponsor

Sameek Roychowdhury (1)

University of California, San Francisco (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

laboratory biomarker analysis (2)

brigatinib (1)

capmatinib (1)

ceritinib (1)

entrectinib (1)

quality-of-life assessment (1)

questionnaire administration (1)

regorafenib (1)

Study Documents

Intervention Type

drug (2)

other (2)

Funder Type

Other (2)

Study Type

Interventional (2)

ros1 fusion positive

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

Withdrawn

Advanced Malignant Neoplasm
+10 more

Brigatinib
+3 more

Columbus, Ohio

Ohio State University Comprehensive Cancer Center

Feb 15, 2022

ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma Trial in San Francisco (Capmatinib, Ceritinib,

Terminated

Has Results

ALK Fusion Protein Expression
+14 more

Capmatinib
+4 more

San Francisco, California

University of California, San Francisco

Jan 14, 2020